Tilmanocept

Navidea Biopharmaceuticals' Lymphoseek gains FDA approval for expanded use in head and neck cancer patients, marking its second indication in the U.S. The radioactive diagnostic imaging agent was initially approved in 2013 for breast cancer and melanoma patients. Navidea has reported increasing revenue from Lymphoseek sales since its launch, with an additional FDA decision pending for more flexible usage practices.

Inari Medical Inc reported a record Q1 2024 revenue of $143 million, marking over 23% growth, driven by strong adoption of PE and DBT therapies, international expansion, and progress towards profitability. The company reaffirmed its goal to achieve sustained operating profitability by the first half of 2025. Inari emphasized its commitment to innovation, market expansion, and generating high-quality clinical data to maintain its leadership in the venous thromboembolism (VTE) market. The company also highlighted its emerging therapies and international business as key growth drivers, with significant progress in Europe, Latin America, and Asia Pacific. Inari is on track for commercial launches in Japan and China, aiming to treat patients by the end of 2024.